Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XRN
1851
Chiron Real Estate Inc
XRN
$491M
| $5.03M | ﹤0.01% |
76,050
+29,221
| +62% | +$1.84M |
|
1852
Nature's Sunshine
NATR
$266M
| $5.02M | ﹤0.01% |
562,138
+27,317
| +5% | +$256K |
|
1853
Pitney Bowes
PBI
$2.25B
| $5M | ﹤0.01% |
1,240,625
-236,083
| -16% | -$1.08M |
|
1854
Lexicon Pharmaceuticals
LXRX
$1.03B
| $4.99M | ﹤0.01% |
1,203,178
+537,799
| +81% | +$2.07M |
|
1855
3D Systems Corp
DDD
$616M
| $4.99M | ﹤0.01% |
570,150
+305,700
| +116% | +$2.65M |
|
|
ECOM
1856
DELISTED
CHANNELADVISOR CORPORATION
ECOM
| $4.99M | ﹤0.01% |
551,900
+116,300
| +27% | +$1.07M |
|
1857
Seneca Foods Class A
SENEA
$1.3B
| $4.98M | ﹤0.01% |
122,100
+43,200
| +55% | +$1.56M |
|
1858
Preformed Line Products
PLPC
$2.27B
| $4.98M | ﹤0.01% |
82,500
+7,100
| +9% | +$442K |
|
1859
Boyd Gaming
BYD
$6.11B
| $4.96M | ﹤0.01% |
165,600
-45,500
| -22% | -$1.28M |
|
|
EFC
1860
Ellington Financial
EFC
$1.76B
| $4.94M | ﹤0.01% |
269,424
+182,624
| +210% | +$3.34M |
|
1861
KVH Industries
KVHI
$145M
| $4.94M | ﹤0.01% |
443,600
-11,500
| -3% | -$122K |
|
|
ARC
1862
DELISTED
ARC Document Solutions, Inc.
ARC
| $4.94M | ﹤0.01% |
3,551,638
+59,864
| +2% | +$78.1K |
|
1863
Corvus Pharmaceuticals
CRVS
$1.25B
| $4.93M | ﹤0.01% |
906,200
+54,422
| +6% | +$190K |
|
1864
MacroGenics
MGNX
$268M
| $4.92M | ﹤0.01% |
452,123
+17,770
| +4% | +$176K |
|
|
CMCM
1865
Cheetah Mobile
CMCM
$103M
| $4.91M | ﹤0.01% |
270,539
+49,600
| +22% | +$888K |
|
|
FTR
1866
DELISTED
Frontier Communications Corp.
FTR
| $4.89M | ﹤0.01% |
5,494,822
+754,837
| +16% | +$615K |
|
|
TEN
1867
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $4.87M | ﹤0.01% |
371,761
-252,639
| -40% | -$3.31M |
|
1868
Aspen Aerogels
ASPN
$485M
| $4.86M | ﹤0.01% |
626,330
+56,799
| +10% | +$392K |
|
1869
Newell Brands
NWL
$2.66B
| $4.86M | ﹤0.01% |
+252,727
| New | +$4.87M |
|
1870
Power Integrations
POWI
$3.51B
| $4.86M | ﹤0.01% |
+98,200
| New | +$4.53M |
|
1871
inTEST
INTT
$179M
| $4.84M | ﹤0.01% |
812,721
+2,787
| +0.3% | +$14.7K |
|
1872
VanEck Fallen Angel High Yield Bond ETF
ANGL
$3.11B
| $4.83M | ﹤0.01% |
161,928
+76,316
| +89% | +$2.24M |
|
1873
Richardson Electronics
RELL
$299M
| $4.83M | ﹤0.01% |
858,071
+26,695
| +3% | +$151K |
|
|
TGP
1874
DELISTED
Teekay LNG Partners L.P.
TGP
| $4.82M | ﹤0.01% |
309,872
+232,140
| +299% | +$3.42M |
|
1875
Cameco
CCJ
$42.6B
| $4.82M | ﹤0.01% |
541,500
+529,300
| +4,339% | +$4.89M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.